Mucosa-associated lymphoid tissue (MALT) lymphoma is a heterogeneous form of a B-cell non-Hodgkin's lymphoma with extranodal location. The gastrointestinal tract is the most common site of disease, but involvement of multiple other organ systems has been documented. Four translocations, t(11;18)(q21;q21), t(1;14)(p22;q32), t(14;18)(q32;q21) and t(3;14)(p13;q32), are specifically associated with MALT lymphoma. Remarkably, the genes targeted by at least three of these translocations are involved in one and the same pathway, leading to the activation of nuclear factor-jB (NF-jB). This review presents MALT lymphoma as a model of how sustained inflammation increases the risk of genotoxic insults and how these genetic events initiate oncogenesis.
Introduction
The neoplastic counterpart of the marginal zone (MZ) is considered to be represented by MZ lymphomas, a group of B-cell non-Hodgkin's lymphomas with an indolent clinical course. Far from being rare, they account for approximately 7-8% of all non-Hodgkin's lymphomas, being the third most frequent subtype (after diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma). MZ lymphomas are subdivided into three entities by the World Health Organization (WHO): splenic MZ lymphoma, nodal MZ lymphoma and mucosa-associated lymphoid tissue (MALT) lymphoma. 1 The latter differs from nodal and splenic MZ lymhomas as it typically arises in sites normally devoid of lymphoid tissue, such as the stomach, lung, the salivary and lachrymal glands, which have accumulated lymphoid tissue in the context of long-standing antigenic stimulation owing to chronic infection, such as gastroduodenal Helicobacter pylori infection, or autoimmune disease. 2 With the progression of the disease, additional oncogenic events may occur, partly owing to the release of reactive oxygen species by neutrophils present in the area of chronic inflammation, which make the lymphoproliferation independent of antigenic stimulation. As such, several genetic aberrations have been identified in MALT lymphomas, some of which appear to be specific for, or at least closely related to, this subtype of MZ lymphoma: the chromosomal translocations t(1;14)(p22;q32), t(14;18)(q32; q21), t(11;18)(q21;q21) and t(3;14)(p13;q32) are all known to occur with variable frequencies in MALT lymphomas, resulting in IGH-BCL10, IGH-MALT1, API2-MALT1 and IGH-forkhead box protein P1 (FOXP1) rearrangements, respectively. [3] [4] [5] [6] The oncogenic activity of t(1;14)(p22;q32), t(14;18)(q32;q21) and t(11;18)(q21;q21) is linked to the involvement of the BCL10 and MALT1 proteins in the antigen-receptor-mediated activation of nuclear factor-kB (NF-kB), which is the transcription factor of a number of survival-and proliferation-related genes in B cells. 7 The oncogenic role of the IGH-FOXP1 fusion transcript is unknown.
(Auto-) antigen-induced acquisition of MALT Growing evidence indicates that MZ lymphomas, and MALT lymphomas in particular, are proceeded by chronic antigenic stimulation. The list of microbial species associated with MZ lymphoproliferations has grown longer with molecular investigations and now comprises at least five distinct members: H. pylori, Campylobacter jejuni Borrelia burgdorferi Chlamydia psittaci and hepatitis C virus (HCV), which have been associated with gastric MALT lymphoma, immunoproliferative small intestinal disease, cutaneous MALT lymphoma, orbital MALT lymphoma and splenic MZ lymphoma, respectively. 2 Gastric MALT lymphoma is strongly associated with gastroduodenal H. pylori infection. In healthy conditions, gastric acid and a thick layer of viscous mucus protect the gastric mucosa and limit bacterial colonization and triggering of lymphoid infiltration. However, H. pylori, a Gram-negative bacterium also associated with peptic ulcers and gastric adenocarcinomas, 8 can survive in this hostile environment by secreting urease to neutralize the local pH. There are several lines of evidence indicating that gastric MALT lymphomas arise from H. pyloriinduced gastric MALT. First, the presence of H. pylori can be demonstrated in the gastric mucosa of 70-90% of the patients with gastric MALT lymphoma, well above the frequency of infection in most populations. 9 Second, the incidence of gastric MALT lymphoma is the highest in regions where H. pylori infection is endemic, such as the Veneto region in northeastern Italy.
10 Third, the seroprevalence of H. pylori is higher in patients with MALT lymphomas. 11 More direct evidence confirming the importance of H. pylori in the pathogenesis of gastric lymphoma has been obtained from in vitro studies, showing that lymphoma growth could be stimulated in culture, when exposed to the organism, through tumour-infiltrating T cells involving CD40 and 40L costimulatory molecules. 12 Also, most clinical and histopathological features of gastric MALT lymphoma can be reproduced by prolonged H. pylori infection of mice. 13 Finally, eradication of H. pylori leads to complete regression of the lymphoma during early stages of the disease in nearly 80% of the cases. 14 Other previously mentioned microorganisms (C. jejuni, B. burgdorferi, C. psittaci) are also linked to the pathogenesis of MALT lymphoma. These associa-tions are primarily based on the detection of the bacteria in the affected tissue and/or on epidemiological studies, 2 but a final proof of causation is not available at the moment.
Furthermore, patients with certain autoimmune diseases are also at increased risk of developing MALT lymphomas. Autoreactive B cells infiltrating the salivary glands in Sjö gren syndrome and the thyroid gland in Hashimoto's thyroiditis progressively organize into a lymphoid infiltrate that reproduces the distinctive histological architecture of normal MALT, including the presence of numerous reactive B-follicles. Patients with Sjö gren syndrome have a 44-fold increased risk of developing a lymphoma; approximately 85% of lymphomas in patients with Sjö gren syndrome are MALT lymphomas. 15 Patients with Hashimoto's thyroiditis have a threefold excess risk of developing lymphoma and a 70-fold increased risk of thyroid lymphoma; 94% of thyroid lymphomas have evidence of thyroiditis in the adjacent gland. 16 Indirect evidence for the role of an (auto)antigen in MZ lymphomagenesis can be deduced from the analysis of the variable part of the immunoglobulin (Ig) heavy chain (V H ) gene. Mutation analysis of these V H genes in MZ lymphoma cells, either occurring at a MALT site, in lymph nodes or in the spleen, has shown somatic hypermutations with a pattern indicative of antigen-selective pressure. 17 In addition, a preferential use of V H 4, V H 3 and V H 1 family genes was noted, with an overrepresentation of some particular V H genes, which seem to be frequently involved in autoantibody production. 17 This restricted use of V H genes in MZ lymphomas further suggests that (auto)antigen stimulation may play a role in lymphomagenesis. Moreover, ongoing mutation (i.e., intraclonal variation) of the IGH gene has been observed in MALT lymphoma, indicating that continuing antigenic stimulation may play a role in the clonal expansion of the tumour cells. 18 
Genetic abnormalities in MALT lymphomas
It is hypothesized that, besides triggering the immunological responses that stimulate the growth of malignant B cells, sustained antigenic stimulation may also trigger inflammatory responses by attracting and activating neutrophils, which release reactive oxygen species. These species are known to be genotoxic and are suspected of causing a wide range of DNA damage, particularly double-strand DNA breaks. 19 The intrinsic genetic instability of B cells during isotype class-switching and somatic hypermutations also increases the risk of oncogenic DNA damage during protracted proliferation associated with inflammation. 20 Cytogenetic data accumulated in recent years have demonstrated several recurring genetic alterations in MALT lymphomas. These abnormalities include aneuploidy, such as trisomy 3, 7, 12 and 18, and a number of chromosomal translocations, being t(1;14)(p22;q32), t(14;18)(q32;q21), t(11;18)(q21;q21) and t(3;14)(p13;q32). The frequency of these genetic aberrations varies considerably according to the anatomic location. 21, 22 t(11;18)(q12;q21)
The t(11;18)(q21;q21) is the most common structural chromosomal abnormality in MALT lymphoma. It has not been described in other B-cell lymphomas and its presence in MALT lymphomas correlates with the lack of any further genetic instability or chromosomal imbalances. 23 The highest incidence of t(11;18)(q21;q21) is observed in MALT lymphomas with a gastric and to a lesser extent pulmonary location (ranging from 10 up to 50%), whereas this translocation is almost never found in MALT lymphomas of other extranodal tissues. 21, 22 It was established that t(11;18)(q21;q21)-positive gastric MALT lymphomas do not respond to H. pylori eradication and are associated with the absence of transformation to a more aggressive DLBCL. 24 Also, its presence in gastric MALT lymphomas was found to be significantly associated with infection by the CagA-positive strains of H. pylori, which induce a strong inflammatory response with release of the potent chemokine interleukin-8 (IL-8) that activates neutrophils with subsequent secretion of reactive oxygen species. 25 Therefore, it is tempting to hypothesize that the t(11;18)(q21;q21) may be related to genotoxic insults caused by inflammatory responses in pre-malignant lesions associated with MALT lymphoma, specifically in mucosal sites that are continuously exposed to exogenous environmental inflammatory stimuli such as the lung and stomach.
The t(11;18)(q21;q21) fuses the amino-terminal of the API2-gene product to the carboxyl-terminal of the MALT1-gene product, thereby generating the chimeric fusion-protein API2-MALT1 3 ( Figure 1 ). The API2 gene (also known as c-IAP2, HIAP1 or MIHC) is located at 11q21 and contains three BIR (baculovirus inhibitor of apoptosis protein repeat) domains, a CARD (caspase recruitment domain) motif and a C-terminal zinc-binding RING (really interesting new gene)-finger domain. The full-length protein product of API2 belongs to the inhibitor of apoptosis protein (IAP) family and suppresses apoptosis by 
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binding to and inhibiting the biological activity of caspases 3, 7 and 9. 26 The MALT1-gene, located at 18q21, comprises an N-terminal death domain (DD), followed by two immunoglobulin-like domains (Ig-I) and a caspase-like domain. Its protein MALT1, classified as a paracaspase, is an essential component involved in the antigen-receptor-mediated activation of NF-kB (see later). 27 The fusion-junctions at the transcript level are well characterized (Figure 1) . 3 All API2 breakpoints are located downstream of the third BIR domain but upstream of the RINGfinger motif, with more than 90% of the breakpoints being located in intron 7, just proximal of the CARD domain, indicating that a common mechanism generates this rearrangement. Conversely, the breakpoints within the MALT1 coding DNA are more variable, occurring in four different introns 2, 4, 7, 8 that are located upstream of the caspase-like domain. As a result, the API2-MALT1 fusion transcript will always comprise the N-terminal API2 region with three intact BIR domains and the C-terminal MALT1 region containing an intact caspase-like domain. In addition, the fusion transcripts are in frame. The specific selection of certain functional domains of API2 and MALT1 to form a functional fusion-product strongly suggests their importance and synergy in oncogenesis. High frequencies of deletions and duplications in both the API2 and MALT1 genomic sequences are also found, which strongly suggests that multiple double-strand DNA-breaks must have occurred during the translocation process. 28 So far, studies have failed to show a specific sequence-mediated chromosomal recombination mechanism involved in the t(11;18)(q21;q21). The t(1;14)(p22;q32) and its variant t(1;2)(p22;p12) occur in less than 5% of MALT lymphomas, which typically display additional genomic abnormalities and tend to be at an advanced stage of disease at diagnosis. 5 This translocation relocates the entire BCL10-gene (also known as CARMEN, CIPER, CLAP, c-E10 or mE10), located at 1p22, to chromosome 14, thereby bringing BCL10 under control of the IGH-gene enhancer. This results in nuclear overexpression of BCL10, as can be demonstrated by standard immunohistochemistry. 29 BCL10 encodes an intracellular protein of 233 amino acids, characterized by an amino-terminal CARD motif and a Ser/Thr-rich carboxylterminus of unknown function. 7 In normal tissues, BCL10 is ubiquitously expressed at low levels. The highest BCL10 expression levels are found in the spleen, lymph node, testis and developing central nervous system. 5 Initially, based on in vitro transfection assays, wild-type BCL10 was thought to be weakly proapoptotic, despite the fact that it activates NF-kB (see later). 5 However, later studies revealed that BCL10 does not have a proapoptotic role in vivo: knockout mice with targeted disruption of BCL10 retained their susceptibility to apoptotic stimuli and were markedly immunodeficient owing to defective NF-kB activation. 30, 31 In line with these observations, transgenic mice in which BCL10 was linked to a construct containing an IGH enhancer showed a marked and specific expansion of the splenic MZ, reminiscent of human MZ lymphoma (Zhang Q et al. Blood 2000; 96: 822; abstract). Therefore, in B cells, it is assumed that wild-type BCL10 promotes proliferation rather than apoptosis.
t(14;18)(q32;q21)
The t(14;18)(q32;q21) was only recently identified and occurs in 2-18% of the MALT lymphomas, depending upon the study performed. 4, 21 Similar to t(1;14)(q21;q21), this translocation is mediated by IGH and leads to overexpression of the MALT1 gene. The 18q21 breakpoint involving the MALT1 gene lies 5 Mb centromeric of the B-cell lymphoma 2 (BCL2) gene, which is targeted by the t(14;18)(q32;q21) characterizing follicular lymphomas. In contrast to t(11;18)(q21;q21)-positive cases, MALT lymphomas marked by t(14;18)(q32;q21) are mainly found outside the gastrointestinal or pulmonary tract, presenting as tumours of the ocular adnexa, skin, liver or salivary glands. 4, 21, 22 Hypothesis is that this polarization reflects a different pathogenesis; that is that MALT lymphomas of the salivary and lachrymal glands are often associated with autoimmune disease, whereas those arising in the stomach and lung are linked to an (un)known infectious agent. In vitro and in vivo experiments have shown that MALT1 might physically associate with BCL10: this interaction involves the two Ig-I of MALT1 and a short stretch of amino acids that follows the CARD-motif of BCL10. 32 In addition, it was revealed that MALT1 is synergistic with BCL10 to enhance NF-kB activation in both B-and T-cells, suggesting that these proteins function in the same pathway (see later).
t(3;14)(p13;q32)
Recently, FOXP1Forkhead box protein P1 was identified as a new translocation partner of IGH in MALT lymphomas (with anatomic site preference for the thyroid, the ocular adnexa, the skin and the stomach) as well as in DLBCL. 6, 33 In both lymphoma subtypes, the overall frequency of FOXP1 -gene rearrangements appears to be relatively low. 6 The FOXP1 -gene is located at 3p13 and codes for a member of the FOX family of transcription factors, which is characterized by a common DNA-binding winged helix or forkhead-domain together with N-terminal zinc-finger and leucine-zipper domains. 34 This family includes numerous proteins that take part in a wide range of normal developmental events, including the control of cellular differentiation and proliferation, immune regulation and signal transduction. Spontaneous mutations of these molecules have been identified in various congenital disorders; also, FOX transcription factors are implicated in carcinogenesis through retroviral integration, transcriptional regulation, chromosomal translocation and gene amplification. 35 Although the physiological role of FOXP1 in lymphoid tissue is still unclear, it has shown to be expressed in normal activated B cells using genomic-scale expression profiling and in mantle zone and some germinal centre (GC) B cells using immunohistochemistry. 34 The significance of FOXP1 overexpression in lymphomas is still debated, but the strong nuclear expression of FOXP1 in MALT lymphomas as well as in a subset of DLBCLs argues for a possible role of FOXP1 in the pathogenesis of these B-cell lymphomas. One study found nuclear FOXP1-positivity to be confined to MALT lymphomas with poor clinical outcome. 36 Deregulation of MALT1 and NF-kB: the unifying concept for MALT lymphomagenesis?
Compelling evidence links the oncogenic activity of the three MALT lymphoma-associated translocations, t(11;18)(q12;q21), t(1;14)(p22;q32) and t(14;18)(q32;q21), to constitutive NF-kB activation caused by the expression of the API2-MALT1 fusion protein or the overexpression of BCL10 and MALT1, respectively. NF-kB plays a central role in the regulation of diverse biological processes, including innate and adaptive immunity, development, cell growth and survival. 37 The mammalian NF-kB family consists of five proteins that share a conserved REL homology domain for DNA binding, called RelA (p65), RelB, c-Rel, p50 and p52 that form various homo-and heterodimers. 37 Whereas the p65, RelB and c-Rel proteins are synthesized directly as mature forms, p50 and p52 have to be generated through processing from their respective precursors, NF-kB1/p105 and NF-kB2/p100. Two major pathways leading to NF-kB activation have been described, termed the canonical or classical and the alternative pathways. 37 The canonical pathway mainly employs p65/p50 dimers and is triggered by proinflammatory cytokines like tumor-necrosis factor-a (TNF-a) and interleukin-1 (IL-1), mitogens and microbial components (such as lipopolysaccharides). In unstimulated cells, p65/p50 dimers are sequestered in the cytoplasm as latent complexes through binding with inhibitory kB (IkB) proteins. Activation of the classical pathway leads to polyubiquitination and activation of IkB kinase-g (IKKg), also known as NF-kB essential modulator (NEMO), resulting in phosphorylation of IkB kinase-b (IKKb). The latter induces the phosphorylation and proteasomal degradation of IkB, which allows the REL-A/p50 dimers to enter the nucleus and mediate transcription of proproliferative genes, such as cyclin D2, and several antiapoptotic genes, including BCL2 and BCL-XL. Conversely, the alternative pathway involves the proteolytic processing of NF-kB2/p100-p52. This pathway is initiated by the NF-kB-inducing kinase (NIK) that phosphorylates IkB kinase-a (IKKa), which in turn phosphorylates p100. Consequently, p100 is polyubiquitinated and processed to the mature p52 subunit by the proteasome, which allows p52/RelB dimers to enter the nucleus.
Antigen stimulation of the B/T-cell receptor induces canonical NF-kB activity (Figure 2) . Studies of knockout mice established an essential role for both BCL10 and MALT1 in transducing antigen-receptor signals to activate the NF-kB pathway. 30, 38, 39 Upon antigen stimulation, CARD11 (CARMA1/Bimp1) recruits BCL10 40 and MALT1 41 to the lipid rafts at the receptor, which is believed to induce the formation of BCL10/MALT1/TRAF6 oligomers. 42 This elicits the E3 ubiquitin ligase activity of the TRAF6 RING domain to synthesize a Lys63-linked polyubiquitin chain on TRAF6 itself and on IKKg, which also binds to CARD11. 43 The latter ubiquitination event is essential for T-cell receptor-mediated NF-kB activation 44 and in contrast to Lys48-linked polyubiquitin chains, which induce proteasomal degradation, Lys63-linked polyubiquitination facilitates the recruitment of downstream signaling components. In this way, polyubiquitinated TRAF6 and NEMO recruit the TAB/TAK1 kinase complex, which fully activates the IKK complex via phosphorylation of the b subunit resulting in phosphorylation Figure 2 The NF-kB pathway in T cells. TCR stimulation and costimulation of CD28 both activate a cascade of tyrosine phosphorylation that converge at lipid raft association and activation of PKCy. In turn PKCy phosphorylates CARD11, which induces a conformational change that enables it to associate with the BCL10-MALT1-TRAF6 complex in the lipid rafts. In parallel, PKCy recruits the IKK complex to the lipid rafts. Caspase-8 is co-recruited to the rafts via its binding to TRAF6 and interconnects the IKK and BCL10-MALT1 complexes. This complex formation is associated with K63-linked polyubiquitination of TRAF6 and NEMO, which facilitates their interaction with the TAB-TAK1 kinase complex. Phosphorylation of IKKb by TAK1 fully activates the IKK complex, which phosphorylates IkB and targets it for degradation by the proteasome. 'Free' NF-kB translocates into the nucleus, where it induces expression of genes essential for the proliferation and function of activated T cells. 42 In conclusion, the lipid raft recruitment of both the BCL10-MALT1-TRAF6 and the IKK complex is of particular importance in this signaling cascade towards NFkB. Although CARD11 is essential for both events, 43, 45 additional proteins have been identified to play a role. Recruitment of protein kinase Cy (PKCy) in the lipid rafts is essential for NF-kB actvation, and has been associated with signals emanating from the T-cell receptor (via Lck/Vav), from CD28 (via PI3K/PDK1) and from the SLAM receptors (via SAP/ Fyn). Following its activation via phosphorylation by PDK1 and Lck, PKCy in turn phosphorylates CARD11 in its linker region. 46 This evokes a conformational change, resulting in an enhanced raft localization of CARD11 and its ability to recruit the BCL10-MALT1-TRAF6 and IKK complex. 47, 48 Additionally, PKCy together with BCL10 seems to be important for the activation of caspase-8 following T-cell receptor stimulation. Caspase-8 had been found to bind the BCL10-MALT1 complex and to be recruited to the lipid rafts upon stimulation of Jurkat cells, probably via direct interaction with TRAF6. 49, 50 Although the exact mechanism is not known, activated caspase-8 seems to be required for recruitment of IKKb to the rafts and in this way for NF-kB activation. 49 Also, FAS-associating protein with death domain (FADD) has been implicated in T-cell receptor signaling to NF-kB as it was found in complex with BCL10-MALT1-Caspase-8 in stimulated Jurkat cells before recruitment of IKKb, 50 but its function remains unclear. Whereas the molecular events linking T-cell receptor stimulation to NF-kB activation have been extensively studied, less is known about the mechanism by which the API2-MALT1 fusion signals to NF-kB. Polyubiquitination of IKKg, essential for antigen receptor-mediated NF-kB activation, is also enhanced by API2-MALT1 expression in cell lines and in MALT lymphomas. The NF-kB activating potential of the fusion depends on the first BIR domain of API2 that is believed to mediate oligomerization of the MALT1 C-terminus and TRAF6.
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51 API2 was originally identified as a protein recruited to the cytosolic domain of the tumor necrosis factor (TNF) receptor II via its association with TRAF1 and TRAF2. 52 The crystal structure of the carboxy-terminal TRAF domain of TRAF2 that interacts with the first BIR domain of API2 predicted trimeric self-association, which could then trigger API2-MALT1 oligomerization. 53 However, mutations of the TRAF2 binding site of API2-MALT1 or TRAF2 deficiency did not affect its oligomerization and NF-kB activation, suggesting that their physical interaction is not required for NF-kB signaling. 54 We observed that the first BIR domain of API2 is involved in the association of the API2-MALT1 fusion with the lipid rafts. In fact, targeting the MALT1 C-terminus to the rafts appeared to be sufficient to activate NF-kB. 55 Likewise, permanent raft association of the fusion protein in splenic lymphocytes from API2-MALT1 transgenic mice and of API2-MALT1-expressing BJAB B cells was associated with increased polyubiquitination of IKKg and NF-kB activity respectively. 55, 56 Raft association might facilitate oligomerization of the API2-MALT1 fusion protein and/or the interaction of its MALT1 domains with downstream signaling components like TRAF6, in this way bypassing the normal antigen requirement for formation of MALT1-TRAF6 oligomers and resulting in constitutive NF-kB activation. A role for TRAF6 is supported by the finding that an API2-MALT1 fusion lacking the C-terminal TRAF6 binding site still resided in the lipid rafts, though it was incompetent to activate NF-kB. 55 On the other hand, a recent study questioned a role for TRAF6 in NF-kB activation by API2-MALT1, 51 which warrants further studies. Controversial as well is the involvement of BCL10 in NF-kB signaling by the API2-MALT1 fusion. Inclusion of both Ig domains of MALT1 conferred a higher NF-kB activating potential to this API2-MALT1 fusion variant, which was attributed to its ability to interact with overexpressed BCL10. 27 Hosokawa et al. 57 failed to demonstrate an interaction with endogenous BCL10, possibly because their fusion variant contained only the second Ig domain of MALT1 which might not be sufficient to engage BCL10. But Hu et al. 58 showed that overexpressed BCL10 interacts with the BIR domains of the API2-MALT1 fusion, and RNA-mediated interference experiments further indicated that BCL10, at least in HeLa cells, is crucial for API2-MALT1 to activate NF-kB. These discrepancies might rise from the kind of API2-MALT1 fusion variant used, the cell systems in which the experiments were performed and the BCL10 expression level (endogenous or overexpressed) and demand clarification.
Another feature of MALT lymphomas with t(1;14)(p22;q32) or t(11;18)(q21;q21) is an unusual nuclear localization of BCL10. In normal lymphoid tissue, BCL10 is weakly expressed in the cytoplasm of GC and MZ B cells. Strong nuclear expression of BCL10 is found in t(1;14)(p22;q32)-positive MALT lymphomas, whereas moderate nuclear expression is associated with the t(11;18)(q21;q21). 21 Other MALT lymphomas, such as those with t(14;18)(q32;q21), are marked by strong perinuclear or diffuse cytoplasmic BCL10 staining. 21 Although a detailed mechanism is not yet known, the change in subcellular location might be caused by disturbed nucleo-cytoplasmic shuttling of BCL10, which is regulated by MALT1. 59 Excess BCL10 induced by the t(1;14) might hamper its nuclear export resulting in nuclear retention, as noticed in splenic MZ B cells of transgenic mice in which BCL10 expression is driven by Ig enhancers (Zhang Q et al. Blood 2000; 96: 822; abstract). The relative shortage of MALT1 owing to the loss of one allele by t (11;18) and the inability of the associated API2-MALT1 fusion to export BCL10 might account for the nuclear retention of BCL10 in MALT lymphomas with t (11;18) . 59 This also explains why transgenic mice that express API2-MALT1 under control of the Em enhancer do not show aberrant nuclear BCL10, as here two functional MALT1 alleles will provide sufficient MALT1 levels for nuclear export of BCL10. It was recently demonstrated that nuclear expression of BCL10 and NF-kB is a highly reliable predictor of H. pylori's independence of gastric MALT lymphoma. 60 In ocular adnexal MALT lymphoma, nuclear BCL10 seemed to correlate with shorter failure-free survival, 61 although this could not be confirmed by another group. 62 Gallardo et al. 63 found a significant association of nuclear BCL10 expression with a higher risk of extracutaneous involvement in primary cutaneous MZ B-cell lymphoma, whereas Li et al. 64 reported the development of a locally aggressive course. Based on these observations, a role for nuclear BCL10 in lymphomagenesis is suggested. However, further studies including a larger number of cases and longer follow-up period will be required to determine more precisely the pathological significance of nuclear BCL10. Furthermore, the nuclear function of BCL10 remains to be investigated. Based on its interaction with transcription factor IIB and its ability to activate transcription as a fusion protein linked to the Gal4-DNA-binding domain in HeLa cells, Liu et al. 65 suggested a role for BCL10 as a transcriptional activator, whereas Yeh et al. 66 found nuclear BCL10 to be involved in the transcriptional activity of NF-kB following TNF-a signaling in MCF7 cells.
Irrespective of a contribution by BCL10, constitutive NF-kB activation by the API2-MALT1 fusion is considered essential for malignant B-cell transformation. In accordance, an antiapoptotic effect of API2-MALT1 upon different stimuli was shown in multiple cell lines. 56, 57 Although this effect could be assigned to a certain extent to the induction of antiapoptotic target genes by API2-MALT1-mediated NF-kB activity, 56, 57, 67 additional causes like direct interaction with apoptosis regulators 57 or interference with other signaling cascades cannot be excluded. Indeed, Ho et al. 56 showed that, besides shortcutting antigen-receptor signaling to NF-kB, API2-MALT1 expression results in an increased NF-kB response to CD40 signaling. This finding could be of significance in vivo, as it has been proposed that chronic antigenic stimulation by H. pylori triggers T-cellmediated B-cell growth via activation of the CD40 pathway early in the development of gastric MALT lymphoma. 68 Finally, the higher stability of API2-MALT1 compared to MALT1 69 and its ability to boost its own expression via NF-kB 70 could add to its transforming capacity.
Although these data support the hypothesis that the API2-MALT1 fusion could drive MALT lymphoma development, transgenic mice that express the fusion under the control of the Em enhancer do not develop lymphoma within 50 weeks. 55 Nevertheless, API2-MALT1 expression triggers the specific expansion of splenic MZ B cells, reminiscent of human MZ lymphoma, and promotes the survival of B cells ex vivo. 55 These observations indicate that MALT lymphoma development requires more than the presence of the API2-MALT1 fusion. This is in line with the hypothesis that MALT-type lymphomagenesis is a multistep process in which additional environmental and microbial or (still unknown) host genetic factors play a pivotal role besides the t(11;18)(q21;q21). This is further supported by our observation that antigenic stimulation of the API2-MALT1 transgenic mice induces a splenic MZ lymphomalike lymphoid hyperplasia of a peculiar B-cell subset that disappeared as soon as the antigenic stimulation faded away (Sagaert et al., Haematologica, in press).
